BACKGROUND: Statins reduce cardiovascular events by about one third; thus two out of three events occurring without any lipid lowering treatment still might happen under statin treatment. One reason may be that lipid targets are not met. The DYSlipidemia International Study (DYSIS) was performed to determine the prevalence of persistent dyslipidemia despite statin treatment in Austria. PATIENTS AND METHODS: Between April 2008 and February 2009, 910 outpatients on current statin treatment and aged ≥ 45 years were recruited by general practitioners, cardiologists, endocrinologists, and internists. A clinical examination was performed and lipid values were obtained under stable statin therapy. The ESC guidelines version 2007 served as criteria to judge the attainment of treatment targets for LDL cholesterol and to reach normal HDL cholesterol and triglyceride levels. In 765 patients a full lipid profile including fasting cholesterol, fasting triglycerides, HDL-cholesterol, and LDL-cholesterol could be obtained. RESULTS: Of our patients, 74.5% had at least one lipid parameter not at target. Specifically, 52.3% did not reach the LDL-cholesterol target as according to the ESC guidelines 2007 - and 56.4% as according to the Austrian lipid consensus 2010 -, 59.1% had above-target total cholesterol levels and 42.5% had elevated triglyceride levels. In 23% of the patients the HDL cholesterol was below levels associated with increased cardiovascular risk. In patients with only one single value beyond normal or targeted level, LDL cholesterol had a prevalence of 24.3%, HDL of 11.9% and triglycerides of 24.5%. In 8.4% of patients, all 3 parameters, LDL-cholesterol, HDL-cholesterol and triglycerides, were out of range. CONCLUSIONS: About three quarters of the Austrian patients under chronic statin therapy in routine clinical practice failed to meet lipid values as set by international and Austrian guidelines. There is an urgent need for more effective strategies to better control dyslipidemia in statin treated patients with the aim of further reducing cardiovascular events.
BACKGROUND: Statins reduce cardiovascular events by about one third; thus two out of three events occurring without any lipid lowering treatment still might happen under statin treatment. One reason may be that lipid targets are not met. The DYSlipidemia International Study (DYSIS) was performed to determine the prevalence of persistent dyslipidemia despite statin treatment in Austria. PATIENTS AND METHODS: Between April 2008 and February 2009, 910 outpatients on current statin treatment and aged ≥ 45 years were recruited by general practitioners, cardiologists, endocrinologists, and internists. A clinical examination was performed and lipid values were obtained under stable statin therapy. The ESC guidelines version 2007 served as criteria to judge the attainment of treatment targets for LDL cholesterol and to reach normal HDL cholesterol and triglyceride levels. In 765 patients a full lipid profile including fasting cholesterol, fasting triglycerides, HDL-cholesterol, and LDL-cholesterol could be obtained. RESULTS: Of our patients, 74.5% had at least one lipid parameter not at target. Specifically, 52.3% did not reach the LDL-cholesterol target as according to the ESC guidelines 2007 - and 56.4% as according to the Austrian lipid consensus 2010 -, 59.1% had above-target total cholesterol levels and 42.5% had elevated triglyceride levels. In 23% of the patients the HDL cholesterol was below levels associated with increased cardiovascular risk. In patients with only one single value beyond normal or targeted level, LDL cholesterol had a prevalence of 24.3%, HDL of 11.9% and triglycerides of 24.5%. In 8.4% of patients, all 3 parameters, LDL-cholesterol, HDL-cholesterol and triglycerides, were out of range. CONCLUSIONS: About three quarters of the Austrian patients under chronic statin therapy in routine clinical practice failed to meet lipid values as set by international and Austrian guidelines. There is an urgent need for more effective strategies to better control dyslipidemia in statin treated patients with the aim of further reducing cardiovascular events.
Authors: James H O'Keefe; Loren Cordain; William H Harris; Richard M Moe; Robert Vogel Journal: J Am Coll Cardiol Date: 2004-06-02 Impact factor: 24.094
Authors: John C LaRosa; Scott M Grundy; David D Waters; Charles Shear; Philip Barter; Jean-Charles Fruchart; Antonio M Gotto; Heiner Greten; John J P Kastelein; James Shepherd; Nanette K Wenger Journal: N Engl J Med Date: 2005-03-08 Impact factor: 91.245
Authors: Kornelia Kotseva; David Wood; Guy De Backer; Dirk De Bacquer; Kalevi Pyörälä; Ulrich Keil Journal: Lancet Date: 2009-03-14 Impact factor: 79.321
Authors: Ian Graham; Dan Atar; Knut Borch-Johnsen; Gudrun Boysen; Gunilla Burell; Renata Cifkova; Jean Dallongeville; Guy De Backer; Shah Ebrahim; Bjørn Gjelsvik; Christoph Herrmann-Lingen; Arno Hoes; Steve Humphries; Mike Knapton; Joep Perk; Silvia G Priori; Kalevi Pyorala; Zeljko Reiner; Luis Ruilope; Susana Sans-Menendez; Wilma Scholte op Reimer; Peter Weissberg; David Wood; John Yarnell; Jose Luis Zamorano; Edmond Walma; Tony Fitzgerald; Marie Therese Cooney; Alexandra Dudina Journal: Eur Heart J Date: 2007-08-28 Impact factor: 29.983
Authors: Allen J Taylor; Todd C Villines; Eric J Stanek; Patrick J Devine; Len Griffen; Michael Miller; Neil J Weissman; Mark Turco Journal: N Engl J Med Date: 2009-11-15 Impact factor: 91.245
Authors: Hana Matejovska Kubesova; Pavel Weber; Hana Meluzinova; Katarina Bielakova; Jan Matejovsky Journal: Wien Klin Wochenschr Date: 2013-07-12 Impact factor: 1.704
Authors: Peter Siostrzonek; Helmut Brath; Robert Zweiker; Heinz Drexel; Robert Hoelzl; Margit Hemetsberger; Kausik K Ray Journal: Wien Klin Wochenschr Date: 2021-12-06 Impact factor: 2.275
Authors: Max Pichler; Dominik Lautsch; Claudia Adler; Karl Bögl; Heinz Drexel; Bernd Eber; Christiane Fauer; Johannes Föchterle; Bernhard Föger; Karin Gansch; Peter Grafinger; Monika Lechleitner; Bernhard Ludvik; Gerald Maurer; Reinhard Mörz; Bernhard Paulweber; Karl Peter Pfeiffer; Rudolf Prager; Gerhard Stark; Hermann Toplak; Otto Traindl; Raimund Weitgasser Journal: Wien Med Wochenschr Date: 2013-08-27